A Phase Ib, Open-Label, Multicenter Study of the Safety and Pharmacokinetics of the Combination of RhuMab 2C4 (Omnitarg), a Recombinant Humanized Antibody to HER2, and Docetaxel (Taxotere) in Patients With Advanced Solid Tumors

Trial Profile

A Phase Ib, Open-Label, Multicenter Study of the Safety and Pharmacokinetics of the Combination of RhuMab 2C4 (Omnitarg), a Recombinant Humanized Antibody to HER2, and Docetaxel (Taxotere) in Patients With Advanced Solid Tumors

Completed
Phase of Trial: Phase I

Latest Information Update: 24 May 2017

At a glance

  • Drugs Pertuzumab (Primary) ; Docetaxel
  • Indications Solid tumours
  • Focus Adverse reactions
  • Sponsors Roche
  • Most Recent Events

    • 24 Nov 2015 Protocol has been amended in time frame of primary endpoint from 4 weeks to approx. 10 months to upto day 15.
    • 07 Jul 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top